Printer Friendly

HOMECARE MANAGEMENT, INC. RESPONDS TO WALL STREET JOURNAL ARTICLE

 RONKONKOMA, N.Y., Oct. 8 /PRNewswire/ -- Clifford E. Hotte, Ph.D., chairman and CEO of Homecare Management, Inc. (HMI) (NASDAQ-NMS: HMIS), stated today, in response to the Oct. 6 Wall Street Journal article, that several statements in the article were inaccurate and misleading.
 Dr. Hotte stated, "First, HMI is not just a mail order pharmacy. Drug delivery is only one of several components of our Lifecare Program, which includes a broad array of comprehensive drug therapies and related support services to patients with chronic medical conditions. HMI currently provides these services primarily to organ transplant recipients who require immunosuppressant drug therapies daily over the course of their lives to avert organ rejection."
 Dr. Hotte continued, "Concerning the Journal's reporting that HMI's prices are sometimes three times as high as competitors', this statement is totally untrue and absurd. HMI is competitive in its drug pricing and its pricing structure is certainly in line with the total care package we provide."
 Dr. Hotte added, "We maintain billing practices which are legal, ethical and moral. Our insurance patients are routinely billed for the portion of our serves not covered by insurance. HMI supports existing and proposed legislation which bans the routine waiver of co-payments. Our patients are provided the care they need regardless of class of payor. We care for patients covered by a broad spectrum of plans...private, Medicare, Medicaid, and charitable. HMI does not discontinue service if a patient has lost the ability to pay. We are in the business of helping transplant patients, not adding to their burden. The drug therapy we provide to patients is part of their life support system and we will not cut off a patient because of financial hardship."
 Dr. Hotte added, "The statement in the Wall Street Journal article that Deborah Frye, transplant coordinator at Columbia Presbyterian Medical Center in New York City, saw prices from HMI that were three times greater than the competitions' prices, was a total inaccuracy. Ms. Frye has provided HMI with a copy of her letter of Oct. 6 to the Wall Street Journal stating she was misquoted and requesting a retraction from the Journal."
 Drew Bergman, HMI's chief financial officer, stated, "I am not aware of unsatisfactory relations with any of our insurance companies. Moreover, because of the lifelong charges associated with immunosuppressive therapies, insurance companies, either directly or through case managers, routinely seek to negotiate reimbursement rates on a case-by-case basis."
 Mr. Bergman further stated, "The Wall Street Journal statement -- `Home infusion of intravenous drugs -- one area HMI has targeted for acquisition...' -- is also inaccurate. HMI does not plan to acquire any company whose primary business is traditional home infusion services."
 Homecare Management, Inc. is a national provider of comprehensive drug therapies and related support services to patients with chronic medical conditions. Through its Lifecare Program, HMI provides these services primarily to organ transplant recipients who require immunosuppressant drug therapies continually over the course of their lives to avert organ rejection.
 -0- 10/8/93
 /CONTACT: Dr. Clifford E. Hotte, president and CEO, or Drew Bergman, CFO of Homecare Management, Inc., 516-981-0034; or Diane Perry, 212-661-8030, or Kathy Brunson, 312-266-7800, both of the Financial Relations Board/
 (HMIS)


CO: Homecare Management, Inc. ST: New York IN: HEA SU:

TW-CK -- NY055 -- 0298 10/08/93 16:17 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1993
Words:549
Previous Article:OREGON $42.9 MILLION GENERAL OBLIGATION BONDS RATED 'AA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:IBM CORP. $925 MILLION SHELF REGISTRATION RATED 'A' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters